Neuropsychiatric symptoms are common in Parkinson's disease (PD) and have a disproportionate impact on quality of life and carer burden. Pharmacological treatment is the main approach in dealing with these symptoms, but it is limited by variable efficacy and risk of drug interactions. Non-pharmacological approaches using the cognitive-behavioural therapy (CBT) model are viable alternatives and in this review paper we summarise the evidence of CBT for three of the most common psychiatric manifestations of PD: depression and anxiety, impulse-control disorders and insomnia. Most studies modified the usual CBT format to include modules accounting for problems specific to PD: activity scheduling around motoric function, motor symptoms as trigger...
Behavioural symptoms such as anxiety, depression and psychosis are common in Parkinson's disease (PD...
Parkinson's disease (PD) is characterized by motor symptoms, but nonmotor symptoms also significantl...
Objective: Anxiety negatively impacts the quality of life of Parkinson’s disease (PD) patients and c...
Neuropsychiatric symptoms are common in Parkinson's disease (PD) and have a disproportionate impact ...
Evidence is reviewed demonstrating that cognitive behavior therapy (CBT) is effective in the treatme...
Nonpharmacological therapies, like cognitive behavioral therapy (CBT), for the treatment of non-moto...
Parkinson's disease [PD] is a heterogeneous neurological disorder that is characterized by motor and...
Parkinson’s disease (PD) is a neurodegenerative disorder most commonly associated with motor sympto...
Background: Anxiety disorders occur in up to 35% of patients with Parkinson's disease (PD) and have ...
Background Anxiety disorders are among the most prevalent and disabling neuropsychiatric syndromes i...
OBJECTIVES: Anxiety is a prevalent but understudied non-motor symptom of Parkinson’s disease (PD), f...
Abstract Parkinson’s Disease (PD) is a neurological condition caused by the loss of dopamine neurons...
Objective: Anxiety negatively impacts the quality of life of Parkinson’s disease (PD) patients and c...
Depression and anxiety affect up to 50% of people with Parkinson's Disease (PD) (Marsh, 2000; Murray...
: Neuropsychiatric symptoms (NPSs) such as affective disorders, psychosis, behavioral changes, and c...
Behavioural symptoms such as anxiety, depression and psychosis are common in Parkinson's disease (PD...
Parkinson's disease (PD) is characterized by motor symptoms, but nonmotor symptoms also significantl...
Objective: Anxiety negatively impacts the quality of life of Parkinson’s disease (PD) patients and c...
Neuropsychiatric symptoms are common in Parkinson's disease (PD) and have a disproportionate impact ...
Evidence is reviewed demonstrating that cognitive behavior therapy (CBT) is effective in the treatme...
Nonpharmacological therapies, like cognitive behavioral therapy (CBT), for the treatment of non-moto...
Parkinson's disease [PD] is a heterogeneous neurological disorder that is characterized by motor and...
Parkinson’s disease (PD) is a neurodegenerative disorder most commonly associated with motor sympto...
Background: Anxiety disorders occur in up to 35% of patients with Parkinson's disease (PD) and have ...
Background Anxiety disorders are among the most prevalent and disabling neuropsychiatric syndromes i...
OBJECTIVES: Anxiety is a prevalent but understudied non-motor symptom of Parkinson’s disease (PD), f...
Abstract Parkinson’s Disease (PD) is a neurological condition caused by the loss of dopamine neurons...
Objective: Anxiety negatively impacts the quality of life of Parkinson’s disease (PD) patients and c...
Depression and anxiety affect up to 50% of people with Parkinson's Disease (PD) (Marsh, 2000; Murray...
: Neuropsychiatric symptoms (NPSs) such as affective disorders, psychosis, behavioral changes, and c...
Behavioural symptoms such as anxiety, depression and psychosis are common in Parkinson's disease (PD...
Parkinson's disease (PD) is characterized by motor symptoms, but nonmotor symptoms also significantl...
Objective: Anxiety negatively impacts the quality of life of Parkinson’s disease (PD) patients and c...